137 related articles for article (PubMed ID: 12462527)
1. Fungemia in a cancer patient caused by fluconazole-resistant Cryptococcus laurentii.
Averbuch D; Boekhoutt T; Falk R; Engelhard D; Shapiro M; Block C; Polacheck I
Med Mycol; 2002 Oct; 40(5):479-84. PubMed ID: 12462527
[TBL] [Abstract][Full Text] [Related]
2. Cryptococcus laurentii fungemia in a low birth weight preterm neonate: India.
Gupta M; Mishra AK; Singh SK
J Infect Public Health; 2018; 11(6):896-897. PubMed ID: 29731340
[TBL] [Abstract][Full Text] [Related]
3. Repeated isolation of Cryptococcus laurentii from the oropharynx of an immunocompromized patient.
Bauters TG; Swinne D; Boekhout T; Noens L; Nelis HJ
Mycopathologia; 2002; 153(3):133-5. PubMed ID: 11998874
[TBL] [Abstract][Full Text] [Related]
4. Cryptococcus laurentii fungemia.
Banerjee P; Haider M; Trehan V; Mishra B; Thakur A; Dogra V; Loomba P
Indian J Med Microbiol; 2013; 31(1):75-7. PubMed ID: 23508435
[TBL] [Abstract][Full Text] [Related]
5. First report of Cryptococcus laurentii meningitis and a fatal case of Cryptococcus albidus cryptococcaemia in AIDS patients.
Kordossis T; Avlami A; Velegraki A; Stefanou I; Georgakopoulos G; Papalambrou C; Legakis NJ
Med Mycol; 1998 Oct; 36(5):335-9. PubMed ID: 10075504
[TBL] [Abstract][Full Text] [Related]
6. Fungaemia due to Cryptococcus laurentii and a review of non-neoformans cryptococcaemia.
Johnson LB; Bradley SF; Kauffman CA
Mycoses; 1998; 41(7-8):277-80. PubMed ID: 9861831
[TBL] [Abstract][Full Text] [Related]
7. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
Trpković A; Pekmezović M; Barać A; Crnčević Radović L; Arsić Arsenijević V
J Mycol Med; 2012 Sep; 22(3):243-8. PubMed ID: 23518082
[TBL] [Abstract][Full Text] [Related]
8. Multi-centre evaluation of the Etest method for antifungal drug susceptibility testing of Candida spp. and Cryptococcus neoformans. BSAC Working Party on Antifungal Chemotherapy.
Warnock DW; Johnson EM; Rogers TR
J Antimicrob Chemother; 1998 Sep; 42(3):321-31. PubMed ID: 9786472
[TBL] [Abstract][Full Text] [Related]
9. Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark.
Hagen F; Hare Jensen R; Meis JF; Arendrup MC
Mycoses; 2016 Sep; 59(9):576-84. PubMed ID: 27061834
[TBL] [Abstract][Full Text] [Related]
10. Fluconazole resistance is not a predictor of poor outcome in patients with cryptococcosis.
Vena A; Muñoz P; Guinea J; Escribano P; Peláez T; Valerio M; Bonache F; Gago S; Álvarez-Uría A; Bouza E
Mycoses; 2019 May; 62(5):441-449. PubMed ID: 30184276
[TBL] [Abstract][Full Text] [Related]
11. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs.
Tay ST; Tanty Haryanty T; Ng KP; Rohani MY; Hamimah H
Mycoses; 2006 Jul; 49(4):324-30. PubMed ID: 16784448
[TBL] [Abstract][Full Text] [Related]
12. Fluconazole resistance in cryptococcal disease: emerging or intrinsic?
Cheong JW; McCormack J
Med Mycol; 2013 Apr; 51(3):261-9. PubMed ID: 22989195
[TBL] [Abstract][Full Text] [Related]
13. Diversity and Antifungal Drug Susceptibility of Cryptococcus Isolates in Thailand.
Worasilchai N; Tangwattanachuleeporn M; Meesilpavikkai K; Folba C; Kangogo M; Groß U; Weig M; Bader O; Chindamporn A
Med Mycol; 2017 Aug; 55(6):680-685. PubMed ID: 27915307
[TBL] [Abstract][Full Text] [Related]
14. Molecular Characterization and Antifungal Susceptibility Testing of Sequentially Obtained Clinical Cryptococcus deneoformans and Cryptococcus neoformans Isolates from Ljubljana, Slovenia.
Tomazin R; Matos T; Meis JF; Hagen F
Mycopathologia; 2018 Apr; 183(2):371-380. PubMed ID: 29064061
[TBL] [Abstract][Full Text] [Related]
15. Cryptococcus neoformans serotype A and Cryptococcus gattii serotype B isolates differ in their susceptibilities to fluconazole and voriconazole.
Khan ZU; Randhawa HS; Chehadeh W; Chowdhary A; Kowshik T; Chandy R
Int J Antimicrob Agents; 2009 Jun; 33(6):559-63. PubMed ID: 19195846
[TBL] [Abstract][Full Text] [Related]
16. Molecular typing and in vitro antifungal susceptibility of Cryptococcus spp from patients in Midwest Brazil.
Favalessa OC; de Paula DA; Dutra V; Nakazato L; Tadano T; Lazera Mdos S; Wanke B; Trilles L; Walderez Szeszs M; Silva D; Hahn RC
J Infect Dev Ctries; 2014 Aug; 8(8):1037-43. PubMed ID: 25116671
[TBL] [Abstract][Full Text] [Related]
17. Cryptococcus laurentii diarrhea post hematopoietic stem cell transplant.
Bhat V; Vira H; Khattry N; Toshniwal M
Transpl Infect Dis; 2017 Apr; 19(2):. PubMed ID: 28083955
[TBL] [Abstract][Full Text] [Related]
18. Correlation of Etest and Neo-Sensitabs diffusion assays on Mueller-Hinton-methylene blue agar with broth microdilution reference method (CLSI-M27-A2) for testing susceptibilities of Cryptococcus neoformans to amphotericin B and fluconazole.
Ochiuzzi ME; Santiso GM; Arechavala AI
Med Mycol; 2010 Sep; 48(6):893-6. PubMed ID: 20370370
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous Cryptococcus laurentii infection in an immunocompetent child.
Molina-Leyva A; Ruiz-Carrascosa JC; Leyva-Garcia A; Husein-Elahmed H
Int J Infect Dis; 2013 Dec; 17(12):e1232-3. PubMed ID: 23791224
[TBL] [Abstract][Full Text] [Related]
20. Activity of VT-1129 against Cryptococcus neoformans clinical isolates with high fluconazole MICs.
Nielsen K; Vedula P; Smith KD; Meya DB; Garvey EP; Hoekstra WJ; Schotzinger RJ; Boulware DR
Med Mycol; 2017 Jun; 55(4):453-456. PubMed ID: 27664991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
